MARKET

MCRB

MCRB

Seres
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.46
+0.63
+2.89%
Pre Market: 22.46 0 0.00% 08:19 06/22 EDT
OPEN
22.50
PREV CLOSE
21.83
HIGH
23.60
LOW
21.86
VOLUME
3
TURNOVER
--
52 WEEK HIGH
38.50
52 WEEK LOW
3.670
MARKET CAP
2.06B
P/E (TTM)
-18.2276
1D
5D
1M
3M
1Y
5Y
Geron, AnPac Bio-Medical Science leads healthcare gainers; Orphazyme, Athira Pharma among major losers
Gainers: Geron (GERN) +22%, AnPac Bio-Medical Science (ANPC) +20%, CureVac (CVAC) +13%, Crinetics Pharmaceuticals (CRNX) +7%, Seres Therapeutics (MCRB) +7%.Losers: Orphazyme (ORPH) -41%, Athira Pharma (ATHA) -41%, Chinook Therapeutics (KDNY) -16%, KemPharm...
Seekingalpha · 3d ago
Former FDA Commissioner Hahn joins VC firm that helped launch Moderna
Chip Somodevilla/Getty Images News Stephen Hahn, an oncologist who served as FDA commissioner as the Trump administration dealt with the COVID-19 pandemic, has joined venture capital firm Flagship Pioneering as
Seekingalpha · 06/15 02:50
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability
/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund V...
PR Newswire - PRF · 06/14 09:00
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics, will present at the JMP Securities Life Sciences Conference on...
Business Wire · 06/10 11:00
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
--Event to be held ahead of Phase 2b ECO-RESET study clinical induction results anticipated in mid-2021, with additional microbiome pharmacology data expected in H2 2021
Business Wire · 06/10 11:00
Microbiome Global Market Report 2021: COVID 19 Growth And Change to 2030
Reportlinker.com announces the release of the report "Microbiome Global Market Report 2021: COVID 19 Growth And Change to 2030" - https://www.reportlinker.com/p06090626/?utm_source=GNW
GlobeNewswire · 06/09 09:38
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
--- Data support a cancer-specific microbiome relationship, with correlation identified between microbiome composition and response to immune checkpoint inhibitor treatment in patients with certain cancers -
Business Wire · 06/04 18:30
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
Benzinga · 06/01 15:48
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MCRB. Analyze the recent business situations of Seres through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MCRB stock price target is 38.00 with a high estimate of 47.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 195
Institutional Holdings: 90.95M
% Owned: 99.21%
Shares Outstanding: 91.68M
TypeInstitutionsShares
Increased
60
4.95M
New
26
4.58M
Decreased
46
5.26M
Sold Out
20
629.39K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.23%
Pharmaceuticals & Medical Research
+0.88%
Key Executives
Chairman/Independent Director
Stephen Berenson
President/Chief Executive Officer/Director
Eric Shaff
Chief Financial Officer/Executive Vice President
David Arkowitz
Executive Vice President/Chief Technology Officer
John Aunins
Chief Human Resource Officer/Executive Vice President
Jayne Gansler
Executive Vice President/Chief Technology Officer
David Ege
Executive Vice President/Chief Scientific Officer
Matthew Henn
Executive Vice President/Secretary
Thomas DesRosier
Executive Vice President
Lisa von Moltke
Executive Vice President
Teresa Young
Senior Vice President - Finance/Chief Accounting Officer
Marcus Chapman
Executive Vice President
Terri Young
Independent Director
Dennis Ausiello
Independent Director
Gregory Behar
Independent Director
Paul Biondi
Independent Director
Willard Dere
Independent Director
Kurt Graves
Independent Director
Richard Kender
Independent Director
Meryl Zausner
No Data
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.